

New England Biolabs Product Specification

<i>Product Name:</i>	<i>KasI</i>
<i>Catalog #:</i>	<i>R0544S/L</i>
<i>Concentration:</i>	<i>5,000 units/ml</i>
<i>Unit Definition:</i>	<i>One unit is defined as the amount of enzyme required to digest 1 µg of pBR322 DNA in 1 hour at 37°C in a total reaction volume of 50 µl.</i>
<i>Shelf Life:</i>	<i>12 months</i>
<i>Storage Temp:</i>	<i>-80°C</i>
<i>Storage Conditions:</i>	<i>500 mM KCl, 20 mM Tris-HCl (pH 7.0), 0.1 mM EDTA, 1mM MgCl₂, 50% Glycerol, 0.10% Triton X-100, 200 µg/ml BSA</i>
<i>Specification Version:</i>	<i>PS-R0544S/L v3.0</i>
<i>Effective Date:</i>	<i>02 Nov 2021</i>

Assay Name/Specification (minimum release criteria)

Blue-White Screening (Terminal Integrity) - A sample of LITMUS38i vector linearized with a 10-fold excess of KasI, religated and transformed into an *E. coli* strain expressing the LacZ beta fragment gene results in <1% white colonies.

Exonuclease Activity (Radioactivity Release) - A 50 µl reaction in CutSmart™ Buffer containing 1 µg of a mixture of single and double-stranded [³H] *E. coli* DNA and a minimum of 5 units of KasI incubated for 4 hours at 37°C releases <0.1% of the total radioactivity.

Ligation and Recutting (Terminal Integrity) - After a 20-fold over-digestion of pBR322 DNA with KasI, >95% of the DNA fragments can be ligated with T4 DNA ligase in 16 hours at 16°C. Of these ligated fragments, >95% can be recut with KasI.

Non-Specific DNase Activity (16 Hour) - A 50 µl reaction in CutSmart™ Buffer containing 1 µg of pBR322 DNA and a minimum of 5 Units of KasI incubated for 16 hours at 37°C results in a DNA pattern free of detectable nuclease degradation as determined by agarose gel electrophoresis.

Protein Purity Assay (SDS-PAGE) - KasI is >95% pure as determined by SDS PAGE analysis using Coomassie Blue detection.

* The BSA in this product has been granted an EDQM "Certificate of Suitability" from the European Directorate for the Quality of Medicines (# R1-CEP-2003-204-Rev00) and has been granted a USDA Certificate for Export of Bovine Blood Plasma/Serum for Manufacture into Pharmaceutical Products.

One or more products referenced in this document may be covered by a 3rd-party trademark.
Please visit www.neb.com/trademarks for additional information.



Date 02 Nov 2021

Derek Robinson
Director, Quality Control

